Skip to main content

Full Schedule

Full Schedule

  • Thursday, March 30, 2023
  • 8:30 AM – 8:45 AM CT
    Welcome
  • 8:45 AM – 9:00 AM CT
    1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant Immunotherapy
  • 9:00 AM – 9:15 AM CT
    1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant Immunotherapy
  • 9:15 AM – 9:30 AM CT
    1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Discussion
  • 9:30 AM – 10:30 AM CT
    Treatment Options for Certain Patients With Select Advanced Upper Gastrointestinal Cancers. Speaker: John Berry, MD
  • 10:30 AM – 10:45 AM CT
    Exhibit Hall
  • 10:45 AM – 11:00 AM CT
    Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined Immunotherapy
  • 11:00 AM – 11:15 AM CT
    Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Chemotherapy
  • 11:15 AM – 11:30 AM CT
    Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DISCUSSION
  • 11:30 AM – 12:15 PM CT
    Session 3: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing
  • 12:15 PM – 1:15 PM CT
    Evolving Biomarker Landscape in Gastric and Gastroesophageal Junction Adenocarcinomas. Speaker: Stephanie Braun
  • 1:15 PM – 2:00 PM CT
    Session 4: Circulating Tumor DNA (ctDNA) in Gastrointestinal Malignancies
  • 2:00 PM – 2:45 PM CT
    6 - Session 5: Integration of Supportive Care
  • 2:45 PM – 3:15 PM CT
    Exhibit Hall
  • 3:15 PM – 4:00 PM CT
    7 - Session 6: Perspectives on Clinical Trial Development in Anal Cancer
  • Friday, March 31, 2023
  • 7:45 AM – 8:00 AM CT
    Welcome
  • 8:00 AM – 8:15 AM CT
    8 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab
  • 8:15 AM – 8:30 AM CT
    9 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab
  • 8:30 AM – 8:45 AM CT
    9 - Session 7: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion
  • 8:45 AM – 9:30 AM CT
    1 - Session 8: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted Therapies
  • 9:30 AM – 10:30 AM CT
    Discover a Treatment Option for Locally Advanced or Metastatic Biliary Tract Cancer. Speaker: Dr. Chih-Yi “Andy” Liao
  • 10:30 AM – 10:45 AM CT
    Exhibit Hall
  • 10:45 AM – 11:30 AM CT
    Session 9: Updates from Recent Meetings
  • 11:30 AM – 11:45 AM CT
    8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRT
  • 11:45 AM – 12:00 PM CT
    8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Chemotherapy
  • 12:00 PM – 12:15 PM CT
    8 - Session 10: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Discussion
  • 12:15 PM – 1:15 PM CT
    Lunch
  • 1:15 PM – 2:00 PM CT
    Session 11: Advances in Neuroendocrine Tumors (NETs)
  • 2:00 PM – 2:15 PM CT
    Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX
  • 2:15 PM – 2:30 PM CT
    Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX
  • 2:30 PM – 2:45 PM CT
    Session 12: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - Discussion
  • 2:45 PM – 3:15 PM CT
    Exhibit Hall
  • 3:15 PM – 4:00 PM CT
    15 - Session 13: The Pillars of Cancer Wellness
  • 4:00 PM – 4:45 PM CT
    14 - Session 14: The Power of Patient Advocacy
  • Saturday, April 1, 2023
  • 7:45 AM – 8:00 AM CT
    Welcome
  • 8:00 AM – 8:15 AM CT
    15 - Session 15: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Yes
  • 8:15 AM – 8:30 AM CT
    15 - Session 15: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - No
  • 8:30 AM – 8:45 AM CT
    15 - Session 15: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Discussion
  • 8:45 AM – 9:30 AM CT
    16 - Session 16: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment Strategies
  • 9:30 AM – 10:30 AM CT
    An Exelixis Product for the Clinical Management of HCC. Speaker: Amit Mahipal, MBBS, MPH
  • 10:30 AM – 10:45 AM CT
    Exhibit Hall
  • 10:45 AM – 11:30 AM CT
    Session 17: Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma
  • 11:30 AM – 12:00 PM CT
    Exhibit Hall
  • 12:00 PM – 12:45 PM CT
    23 - Session 18: Significance of Cancer Genetics
  • 12:45 PM – 1:30 PM CT
    21 - Session 19: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and Gastric